Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4207 | Venous Draw & Testing Wiki | 1.00 |
| drug845 | Capillary Collection & Testing Wiki | 1.00 |
| drug4010 | Thrombin generation test assay Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D004211 | Disseminated Intravascular Coagulation NIH | 0.50 |
| D020141 | Hemostatic Disorders NIH | 0.26 |
| D001778 | Blood Coagulation Disorders NIH | 0.26 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0005521 | Disseminated intravascular coagulation HPO | 0.50 |
| HP:0001928 | Abnormality of coagulation HPO | 0.26 |
Navigate: Correlations HPO
There is one clinical trial.
Increased D-dimers at admission of COVID-19 infected patients entering hospital due to a severe disease is a risk factor for death. Understanding this acquired coagulopathy is a prerequisite before specific interventional studies. The study investigators aim to apply a normalized and automated thrombin generation test (TGT), developed for testing the thrombotic risk (triggered by 5 pM Tissue Factor, with a purified thrombomodulin (TM) challenge) and to study its association with survival.
Description: Death yes/no during hopstilization, 28 days after admittence
Measure: 28-day survival rate Time: 1 monthDescription: Seconds; without (TM-) and with (TM+) purified thrombomodulin
Measure: Absolute thrombin generation test latent period Time: Day 0Description: %; without (TM-) and with (TM+) purified thrombomodulin
Measure: Relative thrombin generation test latent period compared to reference plasma Time: Day 0Description: nmol/s; without (TM-) and with (TM+) purified thrombomodulin
Measure: Absolute thrombin generation test initial velocity Time: Day 0Description: %; without (TM-) and with (TM+) purified thrombomodulin
Measure: Relative thrombin generation test initial velocity compared to reference plasma Time: Day 0Description: %; without (TM-) and with (TM+) purified thrombomodulin
Measure: Relative thrombin generation test peak thrombin compared to reference plasma Time: Day 0Description: nmol/L; without (TM-) and with (TM+) purified thrombomodulin
Measure: Absolute thrombin generation test peak thrombin Time: Day 0Description: Seconds; without (TM-) and with (TM+) purified thrombomodulin
Measure: Absolute thrombin generation test peak thrombin time Time: Day 0Description: %; without (TM-) and with (TM+) purified thrombomodulin
Measure: Relative thrombin generation test peak thrombin time compared to reference plasma Time: Day 0Description: seconds; without (TM-) and with (TM+) purified thrombomodulin
Measure: Absolute thrombin generation test total thrombin generation time Time: Day 0Description: %; without (TM-) and with (TM+) purified thrombomodulin
Measure: Relative thrombin generation test total thrombin generation time compared to reference plasma Time: Day 0Description: Seconds; without (TM-) and with (TM+) purified thrombomodulin
Measure: Absolute thrombin generation test endogenous thrombin potential Time: Day 0Description: %; without (TM-) and with (TM+) purified thrombomodulin
Measure: Relative thrombin generation test endogenous thrombin potential compared to reference plasma Time: Day 0Description: Death yes/no
Measure: 3-month survival rate Time: 3 monthsDescription: Yes/no
Measure: Transfer to intensive care unit during hospitalization Time: 3 monthsDescription: Yes/no (deep vein thrombosis, pulmonary embolism, atherothrombosis flare, arterial thrombosis)
Measure: Thrombotic complication during hospitalization Time: 3 monthsDescription: µg / L, assayed by automated enzyme linked fluorescent assay (Vidas® D-dimers Exclusion ™ II)
Measure: Plasma concentrations of D-dimers Time: Day 0Description: mg / L, measured by automated immunoagglutination (STA®-Liatest® FM)
Measure: Plasma concentrations of soluble fibrin monomers Time: Day 0Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports